Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
about
Structural and biological mimicry of protein surface recognition by / -peptide foldamersPotent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoDefining the fitness of HIV-1 isolates with dual/mixed co-receptor usageChemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compoundsEvidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageNeutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitroStudy of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculationCryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees.A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.Characterization of primary isolate-like variants of simian-human immunodeficiency virusDeterminants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication.Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivityNeutralization profiles of sera from human immunodeficiency virus (HIV)-infected individuals: relationship to HIV viral load and CD4 cell count.Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection.Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 proteinTreatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.Phenotypic Correlates of HIV-1 Macrophage Tropism.Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytesQuantitation of HLA proteins incorporated by human immunodeficiency virus type 1 and assessment of neutralizing activity of anti-HLA antibodies.The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designN-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairsDerivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication.
P2860
Q27657158-EAADF54F-50CE-4D3C-8EF4-AEF58F93CBCDQ28345395-BEB3FAD1-F573-4BD3-8EB9-2085D3E35E2BQ28362194-EB4B7542-22F2-4725-B73B-DBCACACC7FA1Q30278577-94700397-5168-4B6D-84CC-713F4C84FBD6Q33508889-0A8AA5F1-77CF-4BD1-A968-D0AA74727475Q33782296-6D690CE4-EBAD-4BEA-8434-EAEF8BA77D91Q33783714-610A3A94-E1C1-41B6-A4DC-7BCA3497AD5BQ33785490-62E35EBF-BEC5-4830-A2D8-20288236114AQ33786049-8845DD34-9F8F-4885-9479-D0721D6CAFADQ33788701-A09CF217-C97C-47F8-A045-C3D101971754Q33788810-3B66DCAE-0AF1-4E37-8D01-3AE4D12217A3Q33808728-BF44C1B7-1FC9-47C9-80A9-40696C971970Q33810203-EC5F182C-0E92-4388-AD92-6B7F94F05C3CQ33822395-73E0B0BE-B3F6-4512-89DF-A24316209B96Q33825229-D2F01473-67F8-46A0-AF1F-20E0724DB37BQ33825418-E7EA8025-692F-4863-8B2D-FAA87B93957DQ33842286-E4E35342-A602-4443-B6C4-7DCC1EB7A9AEQ33843345-4324D51E-4B2A-48C6-80F5-E2AD9DA877C9Q33848876-EF7C3643-ABB8-43D6-A39C-75F316285F29Q33849755-73327180-DB37-405A-A0D2-A4BA2EDAF629Q33987391-F4FE00F6-C8D4-4BFD-AE1A-D3ACBF51E8F9Q33998352-83A6B0C5-C397-4644-B6DA-E79597299A5EQ34227596-8A2C0253-9CF3-40C1-B395-8E8ACA5273C0Q34434854-B32B0711-5883-4E1E-835F-8C5116149C0FQ34756144-E00047FD-5A68-4715-B873-93EF6DB6E0CFQ35211232-056ED7F0-07D2-420D-A242-3E3452694668Q35547693-7B52E30F-EE54-4966-9DCE-2A7177FD9291Q35634988-0D7E0C2B-EE0C-4486-9C67-8D542CA7B9B6Q36281817-29076645-12B7-47A5-A5B2-98A0346C507BQ36368207-FBF986A4-C473-4A2F-961B-D45943D0B775Q36424011-278C8339-5E87-4DF0-91BD-C1A605F1C44FQ36497712-E0B4FB76-2EA5-4F4E-B84A-6EBFA22DA4EEQ36565090-BD72F65E-EE9C-42BA-AD25-FF18E71D4271Q36826759-CE304DF4-3FA1-456A-9021-6535B1D0AAF6Q37009569-D849E82B-ABD4-4A32-A708-8E2714E941E1Q37034798-2C2AA115-F871-48C4-8E1A-DB85033D1D38Q37145329-22951467-A443-4092-B75C-BF107A821DA1Q37233074-40A1B265-BEFC-4183-B929-8FC61542D9E8Q37356010-53F34EB9-7A69-4235-89D8-A2A43208ADABQ37437748-BE24C914-7E9E-460F-973C-F93BFAFBCCEF
P2860
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Neutralization sensitivity of ...... dependent of coreceptor usage.
@en
Neutralization sensitivity of ...... dependent of coreceptor usage.
@nl
type
label
Neutralization sensitivity of ...... dependent of coreceptor usage.
@en
Neutralization sensitivity of ...... dependent of coreceptor usage.
@nl
prefLabel
Neutralization sensitivity of ...... dependent of coreceptor usage.
@en
Neutralization sensitivity of ...... dependent of coreceptor usage.
@nl
P2093
P2860
P1433
P1476
Neutralization sensitivity of ...... ndependent of coreceptor usage
@en
P2093
D R Littman
H Katinger
J M Binley
J Robinson
V N Kewalramani
P2860
P304
P407
P577
1998-03-01T00:00:00Z